Jul. 3 at 12:33 PM
$ZYBT's FY2024 results show a strategic pivot: Revenue down 12% as they intentionally reduce swine vaccine sales to diversify. Gross margins compressed to 49%, but R&D investments held firm. Completed pet vaccine trials and secured two Category I drug certs - positioning for long-term growth. Nasdaq listing fuels global ambitions, but EPS halved to
$0.03. Transitional pain or smart repositioning?
https://www.prnewswire.com/news-releases/zhengye-biotechnology-holding-limited-announces-fiscal-year-2024-financial-results-302497426.html